ClinicalTrials.gg
CompletedNCT00296530Updated Oct 28, 2016

Study Of Patients With Allergic Rhinitis And Asthma

A Phase 4 interventional study of fluticasone propionate/salmeterol and fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 80 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2016-10-28.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
24th of 146
600 · median 100
Started
2005
with 8 others
Phase 4
52 of 147
1 open now
Registered
13th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 24th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2005, is one of 52 in phase 4, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

Read the detailed description

A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Allergic Rhinitis
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have asthma for at least 3 months prior to the study.
  • Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.
  • Currently have seasonal allergic rhinitis and have had seasonal onset of allergic rhinitis for at least the two previous allergy seasons.
  • Have a positive allergy skin test.

Exclusion criteria

Exclusion Criteria:

  • Have a history of life-threatening asthma.
  • Been hospitalized for asthma within the 6 months prior to the study.
  • Have certain conditions that would make study participation unsafe.

The study doctor will evaluate other inclusion and exclusion criteria.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Morning Peak Expiratory Flow

Secondary outcomes

  1. Total Nasal Symptom Scores Morning Forced Expiratory Volume in 1 Second Asthma Symptom-Free Days Asthma Rescue-Free Days

07

Study locations

80 sites
  • GSK Investigational Site
    Ozark, Alabama 36360, United States
  • GSK Investigational Site
    Tempe, Arizona 85282, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Los Angeles, California 90095-1752, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Palmdale, California 93551, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Jose, California 95128, United States
  • GSK Investigational Site
    Stockton, California 95207, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Lilburn, Georgia 30047, United States
  • GSK Investigational Site
    Marietta, Georgia 30060, United States
  • GSK Investigational Site
    Kenilworth, Illinois 60043, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70503, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Chevy Chase, Maryland 20815, United States
  • GSK Investigational Site
    North Andover, Massachusetts 01845, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Omaha, Nebraska 68130, United States
  • GSK Investigational Site
    Ocean, New Jersey 07712, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Ithaca, New York 14850, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    North Olmsted, Ohio 44070, United States
  • GSK Investigational Site
    Sylvania, Ohio 43560, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Collegeville, Pennsylvania 19426, United States
  • GSK Investigational Site
    Gibsonia, Pennsylvania 15044, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19115, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    East Providence, Rhode Island 02914, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Charleston, South Carolina 29414, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37421, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Austin, Texas 78704, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Dallas, Texas 75231-4307, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    El Paso, Texas 79902, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Houston, Texas 77070, United States
  • GSK Investigational Site
    Killeen, Texas 76542, United States
  • GSK Investigational Site
    Plano, Texas 75093, United States
  • GSK Investigational Site
    San Antonio, Texas 78205, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Murray, Utah 84107, United States
  • GSK Investigational Site
    West Jordan, Utah 84084, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
08

References and documents

Publications

  • This study has not been published in the scientific literature.
  • Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb;31(1):68-75. doi: 10.2500/aap.2010.31.3306. PubMed 20167147 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 27, 2006
Start
Sep 2005
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Oct 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00296530
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 27, 2006
Start date
Sep 2005
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Oct 28, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate · Montelukast

Start the discussion